MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down

Key Takeaways Merck's Q3 adjusted EPS of $2.58 beat estimates and rose 64% year over year.Q3 revenues grew 4% to $17.28B, led by oncology, new drugs and animal health segments.Merck narrowed 2025 sales view to $64.5-$65.0B while raising adjusted EPS forecast.Merck (MRK) reported third-quarter 2025 adjusted earnings per share (EPS) of $2.58, which beat the Zacks Consensus Estimate of $2.36. Earnings increased 64% year over year on a reported basis and 65% excluding foreign exchange (Fx).Revenues in the third ...